Intrinsic value of OpGen - OPGN

Previous Close

$1.29

  Intrinsic Value

$0.00

stock screener

  Rating & Target

str. sell

-100%

Previous close

$1.29

 
Intrinsic value

$0.00

 
Up/down potential

-100%

 
Rating

str. sell

We calculate the intrinsic value of OPGN stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.0

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  12.20
  11.48
  10.83
  10.25
  9.72
  9.25
  8.83
  8.44
  8.10
  7.79
  7.51
  7.26
  7.03
  6.83
  6.65
  6.48
  6.33
  6.20
  6.08
  5.97
  5.88
  5.79
  5.71
  5.64
  5.57
  5.52
  5.47
  5.42
  5.38
  5.34
Revenue, $m
  4
  4
  4
  5
  5
  6
  6
  7
  8
  8
  9
  9
  10
  11
  11
  12
  13
  14
  15
  15
  16
  17
  18
  19
  20
  21
  23
  24
  25
  26
Variable operating expenses, $m
  16
  17
  19
  21
  23
  25
  28
  30
  32
  35
  37
  40
  43
  46
  49
  52
  55
  58
  62
  66
  70
  74
  78
  82
  87
  92
  97
  102
  107
  113
Fixed operating expenses, $m
  5
  5
  5
  5
  6
  6
  6
  6
  6
  6
  6
  6
  7
  7
  7
  7
  7
  7
  8
  8
  8
  8
  8
  8
  9
  9
  9
  9
  9
  10
Total operating expenses, $m
  21
  22
  24
  26
  29
  31
  34
  36
  38
  41
  43
  46
  50
  53
  56
  59
  62
  65
  70
  74
  78
  82
  86
  90
  96
  101
  106
  111
  116
  123
Operating income, $m
  -17
  -19
  -20
  -22
  -23
  -25
  -27
  -29
  -31
  -33
  -35
  -37
  -39
  -42
  -44
  -47
  -49
  -52
  -55
  -58
  -61
  -64
  -68
  -71
  -75
  -79
  -83
  -87
  -92
  -96
EBITDA, $m
  -16
  -18
  -19
  -21
  -23
  -24
  -26
  -28
  -30
  -32
  -34
  -36
  -38
  -40
  -43
  -45
  -48
  -50
  -53
  -56
  -59
  -62
  -66
  -69
  -73
  -76
  -80
  -84
  -88
  -93
Interest expense (income), $m
  0
  0
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  3
  3
  3
  4
  4
  4
  4
  5
  5
  6
  6
  6
  7
  7
  8
  8
  9
  9
  10
Earnings before tax, $m
  -17
  -19
  -21
  -23
  -25
  -26
  -28
  -31
  -33
  -35
  -37
  -40
  -42
  -45
  -48
  -51
  -54
  -57
  -60
  -63
  -67
  -70
  -74
  -78
  -82
  -87
  -91
  -96
  -101
  -106
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -17
  -19
  -21
  -23
  -25
  -26
  -28
  -31
  -33
  -35
  -37
  -40
  -42
  -45
  -48
  -51
  -54
  -57
  -60
  -63
  -67
  -70
  -74
  -78
  -82
  -87
  -91
  -96
  -101
  -106

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  8
  9
  10
  11
  12
  13
  14
  15
  17
  18
  19
  21
  22
  24
  25
  27
  28
  30
  32
  34
  36
  38
  40
  42
  45
  47
  50
  53
  55
  58
Adjusted assets (=assets-cash), $m
  8
  9
  10
  11
  12
  13
  14
  15
  17
  18
  19
  21
  22
  24
  25
  27
  28
  30
  32
  34
  36
  38
  40
  42
  45
  47
  50
  53
  55
  58
Revenue / Adjusted assets
  0.500
  0.444
  0.400
  0.455
  0.417
  0.462
  0.429
  0.467
  0.471
  0.444
  0.474
  0.429
  0.455
  0.458
  0.440
  0.444
  0.464
  0.467
  0.469
  0.441
  0.444
  0.447
  0.450
  0.452
  0.444
  0.447
  0.460
  0.453
  0.455
  0.448
Average production assets, $m
  2
  2
  3
  3
  3
  4
  4
  4
  5
  5
  5
  6
  6
  7
  7
  8
  8
  8
  9
  10
  10
  11
  11
  12
  13
  13
  14
  15
  16
  16
Working capital, $m
  -2
  -3
  -3
  -3
  -4
  -4
  -4
  -5
  -5
  -5
  -6
  -6
  -7
  -7
  -7
  -8
  -8
  -9
  -10
  -10
  -11
  -11
  -12
  -13
  -13
  -14
  -15
  -16
  -16
  -17
Total debt, $m
  2
  3
  4
  5
  5
  6
  7
  8
  9
  10
  11
  12
  13
  15
  16
  17
  18
  20
  21
  23
  24
  26
  28
  30
  31
  33
  35
  38
  40
  42
Total liabilities, $m
  6
  7
  8
  9
  9
  10
  11
  12
  13
  14
  15
  16
  17
  19
  20
  21
  22
  24
  25
  27
  28
  30
  32
  33
  35
  37
  39
  41
  44
  46
Total equity, $m
  2
  2
  2
  2
  3
  3
  3
  3
  4
  4
  4
  4
  5
  5
  5
  6
  6
  6
  7
  7
  8
  8
  9
  9
  10
  10
  11
  11
  12
  12
Total liabilities and equity, $m
  8
  9
  10
  11
  12
  13
  14
  15
  17
  18
  19
  20
  22
  24
  25
  27
  28
  30
  32
  34
  36
  38
  41
  42
  45
  47
  50
  52
  56
  58
Debt-to-equity ratio
  1.390
  1.630
  1.830
  2.010
  2.160
  2.290
  2.410
  2.510
  2.600
  2.680
  2.750
  2.820
  2.880
  2.930
  2.980
  3.020
  3.070
  3.100
  3.140
  3.170
  3.200
  3.230
  3.260
  3.280
  3.300
  3.330
  3.350
  3.370
  3.380
  3.400
Adjusted equity ratio
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -17
  -19
  -21
  -23
  -25
  -26
  -28
  -31
  -33
  -35
  -37
  -40
  -42
  -45
  -48
  -51
  -54
  -57
  -60
  -63
  -67
  -70
  -74
  -78
  -82
  -87
  -91
  -96
  -101
  -106
Depreciation, amort., depletion, $m
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  3
Funds from operations, $m
  -17
  -18
  -20
  -22
  -24
  -26
  -28
  -30
  -32
  -34
  -36
  -39
  -41
  -44
  -46
  -49
  -52
  -55
  -58
  -61
  -65
  -68
  -72
  -76
  -80
  -84
  -88
  -93
  -97
  -102
Change in working capital, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
Cash from operations, $m
  -17
  -18
  -20
  -22
  -23
  -25
  -27
  -29
  -31
  -34
  -36
  -38
  -41
  -43
  -46
  -49
  -51
  -54
  -58
  -61
  -64
  -68
  -71
  -75
  -79
  -83
  -87
  -92
  -97
  -102
Maintenance CAPEX, $m
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
New CAPEX, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
Cash from investing activities, $m
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -4
Free cash flow, $m
  -17
  -19
  -21
  -22
  -24
  -26
  -28
  -30
  -33
  -35
  -37
  -40
  -42
  -45
  -48
  -50
  -53
  -57
  -60
  -63
  -67
  -70
  -74
  -78
  -82
  -86
  -91
  -96
  -100
  -106
Issuance/(repayment) of debt, $m
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
Issuance/(repurchase) of shares, $m
  18
  19
  21
  23
  25
  27
  29
  31
  33
  35
  38
  40
  43
  45
  48
  51
  54
  57
  60
  64
  67
  71
  75
  79
  83
  87
  92
  96
  101
  106
Cash from financing (excl. dividends), $m  
  19
  20
  22
  24
  26
  28
  30
  32
  34
  36
  39
  41
  44
  46
  49
  52
  55
  58
  61
  66
  69
  73
  77
  81
  85
  89
  94
  98
  103
  108
Total cash flow (excl. dividends), $m
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  1
  1
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  3
Retained Cash Flow (-), $m
  -18
  -19
  -21
  -23
  -25
  -27
  -29
  -31
  -33
  -35
  -38
  -40
  -43
  -45
  -48
  -51
  -54
  -57
  -60
  -64
  -67
  -71
  -75
  -79
  -83
  -87
  -92
  -96
  -101
  -106
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -16
  -18
  -20
  -22
  -23
  -25
  -27
  -29
  -32
  -34
  -36
  -39
  -41
  -44
  -46
  -49
  -52
  -55
  -58
  -62
  -65
  -69
  -72
  -76
  -80
  -84
  -89
  -93
  -98
  -103
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -16
  -17
  -17
  -18
  -18
  -18
  -18
  -18
  -18
  -18
  -17
  -16
  -16
  -15
  -14
  -12
  -11
  -10
  -9
  -8
  -7
  -6
  -5
  -4
  -3
  -2
  -2
  -1
  -1
  -1
Current shareholders' claim on cash, %
  31.2
  10.4
  3.5
  1.2
  0.4
  0.1
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company's high-resolution DNA tests are marketed under the Acuitas trade name.

FINANCIAL RATIOS  of  OpGen (OPGN)

Valuation Ratios
P/E Ratio -1.7
Price to Sales 8.2
Price to Book 10.9
Price to Tangible Book
Price to Cash Flow -1.9
Price to Free Cash Flow -1.9
Growth Rates
Sales Growth Rate 33.3%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio 4
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 33.3%
Interest Coverage 0
Management Effectiveness
Return On Assets -165.2%
Ret/ On Assets - 3 Yr. Avg. -188.4%
Return On Total Capital -292.3%
Ret/ On T. Cap. - 3 Yr. Avg. 160.9%
Return On Equity -380%
Return On Equity - 3 Yr. Avg. -404.4%
Asset Turnover 0.3
Profitability Ratios
Gross Margin 50%
Gross Margin - 3 Yr. Avg. 63.9%
EBITDA Margin -450%
EBITDA Margin - 3 Yr. Avg. -369.4%
Operating Margin -475%
Oper. Margin - 3 Yr. Avg. -375%
Pre-Tax Margin -475%
Pre-Tax Margin - 3 Yr. Avg. -397.2%
Net Profit Margin -475%
Net Profit Margin - 3 Yr. Avg. -397.2%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

OPGN stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the OPGN stock intrinsic value calculation we used $3.211007 million for the last fiscal year's total revenue generated by OpGen. The default revenue input number comes from 0001 income statement of OpGen. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our OPGN stock valuation model: a) initial revenue growth rate of 12.2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for OPGN is calculated based on our internal credit rating of OpGen, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of OpGen.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of OPGN stock the variable cost ratio is equal to 433.3%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $5 million in the base year in the intrinsic value calculation for OPGN stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 24.2% for OpGen.

Corporate tax rate of 27% is the nominal tax rate for OpGen. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the OPGN stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for OPGN are equal to 62.1%.

Life of production assets of 4.3 years is the average useful life of capital assets used in OpGen operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for OPGN is equal to -65.6%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $1.400997 million for OpGen - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 6.211 million for OpGen is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of OpGen at the current share price and the inputted number of shares is $0.0 billion.

RELATED COMPANIES Price Int.Val. Rating
LH Laboratory of 163.87 231.36  buy
TROV TrovaGene 0.740 0.09  str.sell
DGX Quest Diagnost 94.71 117.37  hold
ENZ Enzo Biochem 3.14 11.55  str.buy
TTOO T2 Biosystems 4.38 0.01  str.sell
GHDX Genomic Health 75.76 51.74  hold

COMPANY NEWS

▶ OpGen Announces Pricing of Public Offering of Common Stock   [Oct-18-18 08:14AM  GlobeNewswire]
▶ OpGen Announces Proposed Public Offering of Common Stock   [Oct-17-18 04:18PM  GlobeNewswire]
▶ OpGen Provides Business and Preliminary Financial Update   [Oct-15-18 05:35PM  GlobeNewswire]
▶ OpGen signs deal with New York health department to research superbugs   [Sep-24-18 02:40PM  American City Business Journals]
▶ OpGen, Inc. to Host Earnings Call   [02:30PM  ACCESSWIRE]
▶ 5 Top-Ranked Stocks to Benefit From Rising P/E Investing   [Jul-31-18 01:35PM  InvestorPlace]
▶ OpGen, Inc. to Host Earnings Call   [12:15PM  ACCESSWIRE]
▶ OpGen Announces Closing of $12 Million Public Offering   [Feb-07-18 07:30AM  GlobeNewswire]
▶ OpGen regains Nasdaq compliance but Wall Street woes continue   [Feb-06-18 10:07AM  American City Business Journals]
▶ OpGen Regains Compliance With Nasdaq Listing Requirements   [Feb-05-18 07:30AM  GlobeNewswire]
▶ Is OpGen Incs (NASDAQ:OPGN) CEO Incentives Align With Yours?   [Jan-24-18 04:53PM  Simply Wall St.]
▶ OpGen shareholders approve reverse stock split in bid to avoid delisting   [Jan-17-18 09:25PM  American City Business Journals]
▶ Here's whats next for OpGen as it faces delisting threat   [Jan-11-18 02:55PM  American City Business Journals]
▶ ETFs with exposure to OpGen, Inc. : January 2, 2018   [Jan-02-18 11:13AM  Capital Cube]
▶ ETFs with exposure to OpGen, Inc. : December 22, 2017   [Dec-22-17 11:46AM  Capital Cube]
▶ ETFs with exposure to OpGen, Inc. : December 11, 2017   [Dec-11-17 02:05PM  Capital Cube]
▶ OpGen, Inc. to Host Earnings Call   [12:10PM  ACCESSWIRE]
▶ ETFs with exposure to OpGen, Inc. : November 1, 2017   [Nov-01-17 12:30PM  Capital Cube]
▶ Should You Be Concerned About OpGen Incs (OPGN) Investors?   [Oct-19-17 09:17PM  Simply Wall St.]
▶ ETFs with exposure to OpGen, Inc. : October 18, 2017   [Oct-18-17 09:55AM  Capital Cube]
▶ When Will OpGen Inc (OPGN) Run Out Of Money?   [Oct-04-17 12:56PM  Simply Wall St.]
▶ ETFs with exposure to OpGen, Inc. : October 2, 2017   [Oct-02-17 11:00AM  Capital Cube]
▶ ETFs with exposure to OpGen, Inc. : September 19, 2017   [Sep-19-17 06:16PM  Capital Cube]
▶ ETFs with exposure to OpGen, Inc. : August 4, 2017   [Aug-03-17 09:03PM  Capital Cube]
▶ OpGen Announces Closing of $10 Million Public Offering   [Jul-19-17 09:25AM  GlobeNewswire]
▶ OpGen Announces Pricing of $10.0 Million Public Offering   [Jul-13-17 06:00AM  GlobeNewswire]
▶ ETFs with exposure to OpGen, Inc. : May 29, 2017   [May-29-17 12:51PM  Capital Cube]
▶ ETFs with exposure to OpGen, Inc. : May 18, 2017   [May-18-17 01:56PM  Capital Cube]
▶ ETFs with exposure to OpGen, Inc. : May 5, 2017   [May-05-17 04:26PM  Capital Cube]
▶ OpGen Announces 2017 First Quarter Financial Results   [Apr-26-17 04:00PM  GlobeNewswire]
▶ ETFs with exposure to OpGen, Inc. : April 25, 2017   [Apr-25-17 03:44PM  Capital Cube]
▶ ETFs with exposure to OpGen, Inc. : April 5, 2017   [Apr-05-17 05:14PM  Capital Cube]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.